BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

Millipore and Oxford Immunotec Co-develop Plates for Diagnosing and Monitoring Infections

Billererica, MA, USA and Oxford, UK, 21 September 2005 - Millipore Corporation (NYSE:MIL) and Oxford Immunotec Ltd. announced today the co-development of a specially designed microtitre plate for use in clinical diagnostics kits. The new plate further advances the simplicity, cost-effectiveness and performance of Oxford Immunotec’s proprietary T-SPOT technology.

This is the first 8-well strip-based plate customised for use in Enzyme-Linked Immunospot (ELISPOT) methodology compared with typical 96-well plates. It is more economical for users to select the number of wells they require and reduce waste as a result. Utilizing Millipore’s market-leading ELISPOT technology with Immobilon®-P membrane, users can rely on the quality and accuracy of the product.

Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec commented, “We have been consistently impressed by Millipore as a collaboration partner. They have delivered a state-of-the art product on time and on budget.  Pairing our pre-eminent T-SPOT technology for diagnosing and monitoring infectious diseases with a flexible multi-well platform is a key step forward in integrating this test worldwide.”

Oxford Immunotec will incorporate the plate into a second generation of its T-SPOT.TB test kit, a revolutionary new test for tuberculosis. It is set to replace the 100-year old skin test currently used to diagnose this resurgent disease.  Incorporating the new plate will provide greater flexibility and improved performance, while lowering the cost of administering the test.

“Millipore is committed to aligning itself with technology leaders, such as Oxford Immunotec, for the delivery of leading-edge products,” said Jonathan DiVincenzo, Vice President of R&D and Marketing for Millipore’s Bioscience Division. “The first use of the new plate is a test that will greatly improve the control of one of the world’s most profound health problems.”

The two companies entered into this partnership in September 2004. Currently, the plates are in production. Under the terms of the agreement, Oxford Immunotec has exclusive rights to use the plates for in vitro diagnostics with its T-SPOT assay kits.
 

- ENDS -

Notes to editors:

About Oxford Immunotec

www.oxfordimmunotec.com

Oxford Immunotec, the T cell measurement company, is headquartered near Oxford, UK. The Company develops and sells clinical diagnostic products based on its patented T-SPOT technology, which opens up new ways of diagnosing and monitoring infections.   T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T-cell response.

About T-SPOT.TB

T-SPOT.TB is an in vitro T-cell activation assay used for diagnosing TB infection and the first product from Oxford Immunotec using the T-SPOT technology. The product is extremely robust in that it gives a result every time and offers unrivalled and maintained sensitivity in high risk and immunocompromised patient groups. T-SPOT.TB is approved for sale in Europe and is designed to replace the 115 year old tuberculin skin test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market of £600m.

About Millipore Corporation

Millipore is a leading bioprocess and bioscience products and services company, organized into two divisions. The Bioprocess Division offers solutions that optimize development and manufacturing of biologics. The Bioscience Division provides high performance products and application insights that improve laboratory productivity. Millipore has a deep understanding of its customers' research and manufacturing process needs, and offers reliable and innovative tools, technologies and services. The Company employs approximately 4,500 people worldwide and posted revenues of $883 million in 2004.  For more information about Millipore visit www.millipore.com.


FOR FURTHER INFORMATION, PLEASE CONTACT:

 

At Millipore:

 

 

Karen Gobler, Bioscience Communications Manager

Millipore Corporation

17 Cherry Hill Drive

Danvers, MA 01923

 

Tel: +1 978-762-5294

Fax: +1 978-762-5385

Email: karen_gobler@millipore.com

 

At Oxford Immunotec:

 

Dr Peter Wrighton-Smith, CEO

Oxford Immunotec

91 Milton Park

Abingdon

Oxfordshire OX14 4RJ, UK

 

Tel: +44 (0)1235 442780

Fax: +44 (0)1235 442781

Email: info@oxfordimmunotec.com

At Northbank Communications:

(for Oxford Immunotec)

 

Lorna Watson, Account Manager

Northbank Communications Ltd
The Media Village, 131-151 Great Titchfield Street,
London, W1W 5BB, UK

 

Tel: +44 (0)20 7886 8156
Fax: +44 (0)20 7886 8151

Email:www.northbankcommunications.com


PHOTOGRAPH

The 8-well strip-based plates co-developed by Oxford Immunotec and Millipore

T-SPOT is a trademark of Oxford Immunotec. Immobilon and Millipore are registered trademarks of Millipore Corporation.

 
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.